Journals / Turkish Journal of Endocrinology and Metabolism / 2016 / Cilt: 20 - Sayı: 1

Diyabetik Nefropati için Tanısal Belirteç Olarak Visfatin Düşünülebilir mi?

Can Visfatin be Considered as a Diagnostic Marker for Diabetic Nephropathy?

Pages
10–15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Visfatin has a significant correlation with oxidative stress.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In this study, we investigated the role of visfatin in early diabetic nephropathy and its association with oxidative stress, paraoxonase (PON) and arylesterase.
📊
Key Findings & Data:Material and Method: Twenty five diabetic patients with microalbuminuria, 25 diabetic patients with normoalbuminuria and 25 healthy individuals were enrolled in the study.
💡
Conclusion & Impact:Visfatin has a significant correlation with oxidative stress.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: In this study, we investigated the role of visfatin in early diabetic nephropathy and its association with oxidative stress, paraoxonase (PON) and arylesterase. Material and Method: Twenty five diabetic patients with microalbuminuria, 25 diabetic patients with normoalbuminuria and 25 healthy individuals were enrolled in the study. Serum total antioxidant status (TAS), total oxidant status (TOS), PON, arylesterase, free sulfhydryl (SH) group, lipid hydroperoxide (LOOH) and visfatin levels were measured. The ratio of TOS to TAS was accepted as oxidative stress index (OSI). Results: Serum visfatin levels were higher in microalbuminuric diabetic group compared to that in normoalbuminuric diabetic group and healthy control group (p<0.001, for each). Visfatin levels in normoalbuminuric diabetic group were significantly higher compared to healthy control group (p=0.001). Correlation analysis yielded that plasma visfatin levels were negatively correlated with SH, arylesterase, and PON levels (r=-0.444, p<0.001; r=-0.340, p=0.004; r=-0.322, p=0.006, respectively) and that they had a positive correlation with LOOH and OSI levels (r=0.252, p=0.034; r=0.622, p<0.001; respectively). According to logistic regression analysis model, the increased levels of OSI and serum visfatin OSI index clarify 51% of developing microalbuminuria in diabetic patients (sensitivity 78.3% and specificity 83.7%). Discussion: The data of this study reveal that increased serum levels of visfatin have a role in the development of diabetic nephropathy. Visfatin has a significant correlation with oxidative stress.

Özet

Amaç: Bu çalışmada erken diyabetik nefropatide visfatinin rolünü ve bunun oxidatif stres, paraoksanaz (PON) ve arilesteraz ile ilişkisini araştırmaktır.Gereç ve Yöntem: Çalışmaya mikroalbuminurisi olan diyabetik 25 hasta, normoalbuminurisi olan diyabetik 25 hasta ve 25 sağlıklı kişi alındı. Serum toplam antioksidan kapasite (TAK), toplam oksidan kapasite (TOK), PON, arilesteraz, serbest sülfidril (SH) grup, lipid hidroksiperoksid (LOOH) ve visfatin düzeyleri ölçüldü. TOK'un TAK'a yüzde olarak oranlaması oksidatif stres indeksi (OSİ) olarak kabul edildi. Bulgular: Serum visfatin düzeyleri mikroalbuminurik diyabetik grupta normoalbuminurik diyabetik grup ve sağlıklı kontrol gruba göre daha yüksekti (her biri için, p<0,001). Korelasyon analizi visfatin düzeyleri SH, arilesteraz ve PON düzeyleri ile negatif korelasyon (sırasıyla, r=-0,444, p<0,001; r=-0,340, p=0,004; r=-0,322, p=0,006) ve LOOH ve OSİ düzeyleri ile pozitif korleasyon olduğunu vermiştir (sırasıyla, r=0,252, p=0,034; r=0,622, p<0,001). Lojistik regresyon analiz modeline göre serum visfatin ve OSİ düzeylerindeki artış diyabetik hastalarda mikroalbuminuri gelişimini %51 oranında açıklamaktadır (duyarlılık %78,3, özgüllük %83,7). Tartışma: Bu çalışmanın verileri serum visfatin düzeyleri artışının diyabetik nefropati gelişiminde bir rolü olduğunu ortaya koymuştur. Visfatin, oksidatif stres ile önemli korelesyon göstermektedir.

🔖

Cite This Article

TABUR, S., KORKMAZ, H., EREN, M. A., OĞUZ, E., SABUNCU, T., KUL, S., AKSOY, N. (2016). Diyabetik Nefropati için Tanısal Belirteç Olarak Visfatin Düşünülebilir mi?. Turkish Journal of Endocrinology and Metabolism, Cilt: 20 - Sayı: 1, 10–15. https://ajindex.com/articles/370806

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am 2013;97:1-18.
  2. Araki S, Haneda M, Koya M, Kashiwagi A, Uzu T, Kikkawa R. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;82(Suppl 1):54-58.
  3. Sethi JK, Vidal-Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11:344-347.
  4. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, Han JY, Han SY, Han KH, Kim HK, Cha DR. Visfatin: A new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008;295:1485-1494.
  5. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-2916.
  6. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295- 299. Mima A. Inflammation and oxidative stress in diabetic nephropathy: New insights on its inhibition as new therapeutic targets. J Diabetes Res 2013;2013:248563. Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Nollino L, Cosma C, Fedele D, Lapolla A. Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 2009;52:1419-1425.
  7. Zhang LQ, Adyshev DM, Singleton P, Li H, Cepeda J, Huang SY, Zou X, Verin AD, Tu J, Garcia JG, Ye SQ. Interactions between PBEF and oxidative stress proteins--a potential new mechanism underlying PBEF in the pathogenesis of acute lung injury. FEBS Lett 2008;582:1802-1808.
  8. Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK- independent, NFkB-dependent manner. Pflugers Arch 2010;459:619- 630. Buldak RJ, Polaniak R, Buldak L, Mielanczyk L, Kukla M, Skonieczna M, Dulawa-Buldak A, Matysiak N, Zwirska-Korczala K. Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma Me45 cells. J Physiol Pharmacol 2013;64:377-385.
  9. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(Suppl 2):64-78. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33:62-69. Er